The future of incentive compensation in the life sciences is being shaped by four major trends: omnichannel engagement, dynamic targeting, ecosystem team models, and the integration of agentic AI.
Omnichannel programs are driving the adoption of new KPIs that reward representatives for effective use of multiple customer touchpoints. Dynamic targeting enables more frequent and flexible prioritization of field targets, prompting IC plans to become more agile, with regular updates to sales crediting and goal setting. The ecosystem team model fosters collaboration by organizing field teams into integrated regional units with shared objectives. Meanwhile, GenAI-driven IC agents – AI-powered tools or systems designed to automate and optimize incentive compensation processes – are revolutionizing IC plan design and management by automating insights, personalizing communications, and optimizing compensation plans.
Field teams are at the center of these industry trends, with evolving expectations for multi-channel engagement, more dynamic and frequent targeting, increased collaboration, and the adoption of AI-driven tools to enhance performance and compensation management. Hence, it is essential that incentive compensation leaders stay up to date on the latest industry trends and best practices if they are to design incentive plans that align with business strategy and drive sales force performance. Axtria conducted its 2026 Incentive Compensation Benchmarking Study across 43 pharmaceutical organizations in the US to develop a robust and holistic set of anonymized benchmarks. These benchmarks will enable organizations to make informed decisions about the design of their incentive compensation plans.
Key areas covered in the complete study include:
- IC target pay and pay mix
- Common incentive plan design practices
- MBO prevalence and the most common objectives
- Maturity of industry trends in IC
- Data sources, sales-crediting, and goal-setting methodologies
- Annual award design approaches, contest budgets, and targeted win rates
Pharmaceutical companies are proactively refining their incentive compensation strategies to keep pace with shifting industry dynamics. Success increasingly depends on aligning incentive structures with performance goals.
Download Axtria’s 2026 US Incentive Compensation Benchmarking Study that offers actionable insights to help organizations evaluate and enhance their compensation programs. By leveraging these benchmarks, companies can drive greater performance, profitability, and innovation, ensuring they remain ahead of emerging trends and continue to advance their business objectives.
FAQs
